We Are Kairos Pharma

Led by the Clinical Chief of Neurosurgery and Director of Surgical Neuro-Oncology at Cedars Sinai Medical Center.

Developing A Diversified Pipeline That Targets Resilient Cancers.

Led by the Clinical Chief of Neurosurgery and Director of Surgical Neuro-Oncology at Cedars Sinai Medical Center.

Developing A Diversified Pipeline That Targets Resilient Cancers.


Uniquely positioned to advance our novel drug development pipeline of peptide and small molecule cancer immunotherapeutics: KROS-101, 102, 201, 301, and 401 as well as therapeutic agents ENV105 and ENV205 for drug resistance.


Industry leading team with a strong track record of drug development, commercialization and multiple M&A exits.

Uniquely positioned to advance our novel drug development pipeline of peptide and small molecule cancer immunotherapeutics: KROS-101, 102, 201, 301, and 401 as well as therapeutic agents ENV105 and ENV205 for drug resistance

Industry leading team with a strong track record of drug development, commercialization and multiple M&A exits.


Proprietary technologies were licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western U.S. providing infrastructure and support to further advance development.


Multi-year plan in place to have IND for Phase II ENV105 prostate cancer clinical trial and Phase I KROS-201 glioblastoma clinical trial IND in 2022. Phase I ENV105 for non-small cell lung cancer IND submission in 2022.

Proprietary technologies were licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western U.S. providing infrastructure and support to further advance development.

Multi-year plan in place to have IND for Phase II ENV105 prostate cancer clinical trial and Phase I KROS-201 glioblastoma clinical trial IND in 2022. Phase I ENV105 for non-small cell lung cancer IND submission in 2022.


Disciplined focus on IP, exclusive world-wide patent licenses.


High value market - targeting a fast growing $311 Billion drug industry.

Disciplined focus on IP, exclusive world-wide patent licenses.

High value market - targeting a fast growing $311 Billion drug industry.

LogoMakr-3fdTSM

OUR MISSION

Kairos Pharma is a clinical stage biopharmaceutical company that harnesses immunity against cancer and drug resistance.

By doing so, we seek to transform the way cancer is treated by positively impacting patient outcomes while maintaining quality of life.

LogoMakr-3fdTSM

OUR MISSION

Kairos Pharma is a clinical stage biopharmaceutical company that harnesses immunity against cancer and drug resistance.

By doing so, we seek to transform the way cancer is treated by positively impacting patient outcomes while maintaining quality of life.

Stay up to date with our latest global news, events and more.